



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	☼ J-Lat GFP Cells (A72)
Catalog Number:	9856
Lot Number:	180427
Release Category:	C
Provided:	800 uL of cells Post thaw cell count = 2.84×10^6 cells/Vial Post thaw cell viability = 52 % Cell viability increased to 89% after 12 days in culture.
Cell Type:	Human T cell lymphoblast
Propagation Medium:	RPMI 1640, 90%; fetal bovine serum, 10%; 2mM GlutaMAX™- I (100X)
Freeze Medium:	Gibco Recovery™ Cell Culture Freezing Medium.
Morphology:	Lymphocytic, Suspension Cell Line
Sterility:	Negative for mycoplasma, bacteria, and fungi
Description:	This is a Jurkat-based cell line containing a single integration site of a HIV retroviral vector expressing LTR driven GFP expression.
Special Characteristics:	Jurkat cells were infected with viral particles bearing the retroviral construct LTR-Tat-IRES-GFP. Cells that were GFP negative, but could be stimulated to express GFP were selected. For the other similar cells, please see cat#s 9846-9856.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Recommended Storage: Keep the reagent in liquid nitrogen.

Contributor: Dr. Eric Verdin.

References: Jordan, A., D. Bisgrove and E. Verdin. (2003). HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J, 22(8), 1868-77. doi:10.1093/emboj/cdg188 [PUBMED](#)

Jordan, A., P. Defechereux and E. Verdin. (2001). The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J, 20(7), 1726-38. doi:10.1093/emboj/20.7.1726 [PUBMED](#)

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: J-Lat GFP Cells (A72) from Dr. Eric Verdin (cat# 9856)." Also include the references cited above in any publication.

These cells and methods of use are covered by US Patents 7,232,685 and 7,544,467.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the J. David Gladstone Institutes, Email: veronica.viray@gladstone.ucsf.edu, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated November 16, 2020

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.